More articles from 05.01 - Airway pharmacology and treatment

Effectiveness of initiating biologics in severe asthma patients with high steroid exposure
W Chen, T N Tran, M Sadatsafavi, E Garcia Gil, M Alacqua, A Menzies Gow, L G Heaney, P E.Pfeffer, J Maspero, M Peters, G C Christoff, M Bhutani, C A.Torres-Duque, C Ulrik, A Altraja, L Lehtimaki, C Taille, A I.Papaioannou, S Salvi, R W Costello, G Walter Canonica, T Iwanaga, M Al-Ahmad, D Larenas-Linnemann, P Kuna, J A.Fonseca, R Al-Lehebi, M Koh Siyue, C K Rhee, L Perez-De-Llano, R C Jones, D Perng, E Wang, F Hoyte, N Wong Chong Boon, J Lyu, C Ariti, R Murray, C Goh, I Joshi, N Eleangovan, D Price

European Respiratory Journal Sep 2022, 60 (suppl 66) 3405; DOI: 10.1183/13993003.congress-2022.3405
Calcaratarin D reduces airway inflammation and oxidative damage by modulating alveolar macrophages via Michael acceptor system
W Liao, Y C H Foo, T N Q Tran, W F Wong

European Respiratory Journal Sep 2022, 60 (suppl 66) 2586; DOI: 10.1183/13993003.congress-2022.2586
Cysteinyl-maresin 3 inhibits IL-13 induced airway hyperreactivity through alternative activation of the CysLT1 receptor
J Säfholm, W Abma, C E. Wheelock, S Dahlén, M Adner

European Respiratory Journal Sep 2022, 60 (suppl 66) 2519; DOI: 10.1183/13993003.congress-2022.2519
Asthma exacerbations and eosinophilia in the UK Biobank: a Genome-Wide Association Study
A Edris, K Fawcett, I P Hall, M D Tobin, L Lahousse

European Respiratory Journal Sep 2022, 60 (suppl 66) 2525; DOI: 10.1183/13993003.congress-2022.2525
Extrafine triple therapy shows improved efficacy compared to ICS/LABA in a mouse model of asthma
D Miglietta, A R Pisano, A Allen, D Fragni, G Federico, F Bignami, E Zambelli, R Zecchi, F Boscaro, B Pioselli, V Mileo, M Civelli, G Villetti

European Respiratory Journal Sep 2022, 60 (suppl 66) 3021; DOI: 10.1183/13993003.congress-2022.3021
Antimicrobial properties of Gallium Protoporphyrin in COPD
J Baker, A Baba-Dikwa, S Lea, D Singh

European Respiratory Journal Sep 2022, 60 (suppl 66) 2876; DOI: 10.1183/13993003.congress-2022.2876
Comorbidities in severe and non-severe asthma: a nationwide population-based observational study
H Kankaanranta, A Viinanen, P Ilmarinen, J Mehtälä, T Ylisaukko-Oja, J J Idänpään-Heikkilä, L Lehtimäki

European Respiratory Journal Sep 2022, 60 (suppl 66) 2966; DOI: 10.1183/13993003.congress-2022.2966
Effects of anti-IL 17 on inflammation in Asthma, COPD and Asthma-COPD models
F M Almeida, L N Camargo, N Martins, J D Lourenço, S K M Bezerra, B Saraiva-Romanholo, E A Leick, F D Q.S. Lopes, C M Prado, R F Righetti, I F L C Tibério

European Respiratory Journal Sep 2022, 60 (suppl 66) 2570; DOI: 10.1183/13993003.congress-2022.2570
Mepolizumab therapy in severe asthma – a study of long term efficacy and safety
C Reilly, R Anandavelu, J Marsh, J Sullivan, F O'Riordran, S Cotterill, L White, A Mansur

European Respiratory Journal Sep 2022, 60 (suppl 66) 2734; DOI: 10.1183/13993003.congress-2022.2734
Decision outcomes following referral to a tertiary severe asthma service for MAb therapy.
A Nuttall, H Joplin, C Lowe, G Jones, S Zaidi, H Burhan, L Chishimba

European Respiratory Journal Sep 2022, 60 (suppl 66) 2797; DOI: 10.1183/13993003.congress-2022.2797

Main menu

User menu

Search

More articles from 05.01 - Airway pharmacology and treatment

Pages

Contact us